Sylvester Comprehensive Cancer Center

  • 20231136 - Bilusic Marijo

  • Investigator:
    Marijo Bilusic
    RCname Email

    		Coordinator:

    IRB: 20231136

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Bladder,Kidney,Other Female Genital,Prostate
    Sponsor: Marengo Therapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
    Eligibility Criteria - NCT05592626 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231317 - Chauhan Aman

  • Investigator:
    Aman Chauhan
    RCname Email

    		Coordinator:

    IRB: 20231317

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Esophagus,Lung
    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    DAREON-7: A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (NEC)
    Eligibility Criteria - NCT06132113 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231318 - Chauhan Aman

  • Investigator:
    Aman Chauhan
    RCname Email

    		Coordinator:

    IRB: 20231318

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Lung
    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    DAREONTM-9: A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with a single agent chemotherapy for the treatment of patients with relapsed/refractory small cell lung cancer after platinum-based chemotherapy
    Eligibility Criteria - NCT05990738 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231325 - Chauhan Aman

  • Investigator:
    Aman Chauhan
    RCname Email

    		Coordinator:

    IRB: 20231325

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors
    Eligibility Criteria - NCT06889493 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220774 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20220774

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Brain and Nervous System
    Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1, Safety Lead In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma
    Eligibility Criteria - NCT05484622 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240209 - De La Fuente Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:

    IRB: 20240209

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Single-Patient Expanded Access Request (Compassionate Use) for the Treatment of Recurrent, BRAF V600E mutant, WHO Grade 2 Pleomorphic Xanthoastrocytoma with ABM-1310

  • 20231030 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    		Coordinator:

    IRB: 20231030

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Rectum
    Sponsor: Iterion Therapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma
    Eligibility Criteria - NCT05797805 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240464 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    		Coordinator:

    IRB: 20240464

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Soft Tissue
    Sponsor: NCI

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin ( (Doxil) in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
    Eligibility Criteria - NCT05711615 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230307 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20230307

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Larynx,Lip, Oral Cavity and Pharynx,Lung,Other Respiratory and Intrathoracic Organs
    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1, Open-Label, Dose Escalation And Dose Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Anti Tumor Activity Of Pf-07799933 (Arry-440) As A Single Agent And In Combination Therapy In Participants 16 Years And Older With Advanced Solid Tumors With Braf Alterations
    Eligibility Criteria - NCT05355701 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231267 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20231267

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Kidney,Lung
    Sponsor: BEIGENE

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT05981703 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240093 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20240093

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Lung
    Sponsor: Nuvalent

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients with Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
    Eligibility Criteria - NCT06521554 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240477 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20240477

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Breast,Lung
    Sponsor: SystImmune Inc

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
    Eligibility Criteria - NCT06293898 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240633 - Lopes Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    		Coordinator:

    IRB: 20240633

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Lung
    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
    Eligibility Criteria - NCT06561685 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210034 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    		Coordinator:

    IRB: 20210034

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Esophagus,Lung,Melanoma, skin,Ovary,Prostate,Unknown Sites
    Sponsor: Dragonfly Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
    Eligibility Criteria - NCT04423029 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230990 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    		Coordinator:

    IRB: 20230990

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple
    Sponsor: TScan Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T
    Eligibility Criteria - NCT05973487 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231004 - Lutzky Jose

  • Investigator:
    Jose Lutzky
    RCname Email

    		Coordinator:

    IRB: 20231004

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple
    Sponsor: TScan Therapeutics

    Enrolling Sites:

    Aventura
    Sylvester
    UMH
    Title:

    Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors
    Eligibility Criteria - NCT05812027 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230681 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:

    IRB: 20230681

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple
    Sponsor: Arcus Biosciences

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy and in combination therapies in participants with clear cell renal cell carcinoma and other solid tumors
    Eligibility Criteria - NCT05536141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230988 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:

    IRB: 20230988

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Kidney,Ovary,Rectum
    Sponsor: DynamiCure Biotechnology

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors
    Eligibility Criteria - NCT05785754 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240538 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:

    IRB: 20240538

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Bladder,Cervix Uteri,Colon,Prostate,Rectum
    Sponsor: Kalivir Immunotherapeutics

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT06444815 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240570 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:

    IRB: 20240570

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Colon,Pancreas,Rectum
    Sponsor: Ikena Oncology

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A FIRST-IN-HUMAN STUDY OF IK-595, AN ORAL DUAL MEK/RAF INHIBITOR, IN PATIENTS WITH RAS- OR RAF-ALTERED ADVANCED SOLID TUMORS
    Eligibility Criteria - NCT06270082 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240092 - Olazagasti Coral

  • Investigator:
    Coral Olazagasti
    RCname Email

    		Coordinator:

    IRB: 20240092

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Lung
    Sponsor: CDR-Life Inc

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors
    Eligibility Criteria - NCT06402201 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240308 - Sharma Janaki

  • Investigator:
    Janaki Sharma
    RCname Email

    		Coordinator:

    IRB: 20240308

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Other Female Genital,Other Respiratory and Intrathoracic Organs,Ovary,Prostate
    Sponsor: EMD

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    An Open-label, Multicenter Phase 1b Study of the Safety, Tolerability, and Pharmacokinetic /Pharmacodynamic Profile of the ATR Inhibitor M1774 in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients with Metastatic or Locally Advanced Unresectable Solid Tumors
    Eligibility Criteria - NCT05396833 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201378 - Tang Jennifer

  • Investigator:
    Jennifer Tang
    RCname Email

    		Coordinator:

    IRB: 20201378

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Other Skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES ARTACUS
    Eligibility Criteria - NCT04349436 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220980 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20220980

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Multiple
    Sponsor: IDRX

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A First-In-Human (FIH) Study Of Idrx-42 In Participants With Metastatic And/Or Unresectable Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT05489237 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230891 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20230891

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Bones and Joints,Soft Tissue
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
    Eligibility Criteria - NCT05957367 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240847 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20240847

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Bones and Joints,Soft Tissue
    Sponsor: DECIPHERA

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT06630234 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240908 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20240908

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Soft Tissue
    Sponsor: Adcendo ApS

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma
    Eligibility Criteria - NCT06797999 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230286 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20230286

    		SDG: Phase I (Non LLM)
    Disease Site(s):

    Bladder,Bones and Joints,Breast,Kidney,Lung,Prostate
    Sponsor: SILLAJEN INC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors
    Eligibility Criteria - NCT05768932 *This information has been extracted from " www.clinicaltrials.gov"